1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Mania - Pipeline Review, H1 2013

Mania - Pipeline Review, H1 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 37 pages

Mania - Pipeline Review, H1 2013


Summary


Global Markets Direct’s, 'Mania - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Mania, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mania. Mania - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope


- A snapshot of the global therapeutic scenario for Mania.
- A review of the Mania products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Mania pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy


- Identify and understand important and diverse types of therapeutics under development for Mania.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Mania pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Mania - Pipeline Review, H1 2013
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mania Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Mania 7
Mania Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Pre-Clinical Stage Products 11
Comparative Analysis 11
Mania Therapeutics - Products under Development by Companies 12
Companies Involved in Mania Therapeutics Development 13
Gedeon Richter Plc. 13
Newron Pharmaceuticals S.p.A. 14
Reviva Pharmaceuticals Inc. 15
Mania - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
cariprazine hydrochloride - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
cariprazine hydrochloride - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
NW-3509 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Mania Therapeutics - Drug Profile Updates 26
Mania Therapeutics - Dormant Products 31
Mania - Product Development Milestones 32
Featured News and Press Releases 32
May 16, 2013: Forest Labs To Present Phase III Trial Data Of Cariprazine At American Psychiatric Association Annual Meeting 32
Oct 05, 2011: Forest Laboratories And Gedeon Richter Announce Positive Phase III Results Of Cariprazine In Acute Mania Associated With Bipolar I Disorder 33
Oct 10, 2008: FDA Approves AstraZeneca's Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania in the US 33
Jun 30, 2008: Janssen Announces Launch of Authorized Generic for RISPERDAL 34
Aug 22, 2007: Johnson's Risperdal Approved By FDA For The Treatment Of Schizophrenia In Adolescents And Bipolar Mania In Children and Adolescents 34
Jun 21, 2007: Johnson's Risperdal Received Approval From FDA To Treat Adolescents With Schizophrenia And Children And Adolescents With Bipolar Mania 35
Mar 01, 2007: Risperdal Received Pediatric Exclusivity From FDA 35
Dec 05, 2003: Risperdal Approved By FDA for The Treatment of Bipolar Mania 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables


Number of Products Under Development for Mania, H1 2013 7
Products under Development for Mania - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Gedeon Richter Plc., H1 2013 13
Newron Pharmaceuticals S.p.A., H1 2013 14
Reviva Pharmaceuticals Inc., H1 2013 15
Assessment by Monotherapy Products, H1 2013 16
Assessment by Stage and Route of Administration, H1 2013 18
Assessment by Stage and Molecule Type, H1 2013 20
Mania Therapeutics - Drug Profile Updates 26
Mania Therapeutics - Dormant Products 31

List of Figures


Number of Products under Development for Mania, H1 2013 7
Products under Development for Mania - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Pre-Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 16
Assessment by Route of Administration, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 18
Assessment by Molecule Type, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.